改良他汀序贯疗法对非介入心肌梗死的影响

目的 探讨改良他汀序贯疗法对非介入治疗急性心肌梗死患者的早期预后.方法 112例急性心肌梗死患者,均未行介入治疗,随机分为观察组（采用改良他汀序贯疗法,58例）和对照组（口服阿托伐他汀20 mg/d,54例）.检测治疗前及治疗6个月后的超敏C反应蛋白.记录急性心肌梗死后6个月主要心血管事件,观察药物不良反应.结果 与对照组比较,应用改良他汀序贯疗法的患者治疗6个月后超敏C反应蛋白明显降低（P ＜ 0.05）.与对照组比较,应用改良他汀序贯疗法的患者急性心肌梗死后6个月主要心血管事件明显降低（P ＜ 0.05）.随访期间,观察组和对照组均无肌毒性和肝毒性事件发生无差别.结论 改良他汀序贯疗法可降低非介入治疗急性心肌梗死患者治疗6个月后超敏C反应蛋白并减少主要心血管事件.

Effects of early statins sequential therapy in patients with acute myocardial infarction and without percutaneous coronary intervention

Objective To investigate the effects of early statins sequential therapy in patients with acute myocardial infarction(AMI) and without percutaneous coronary intervention(PCI).Methods Totally 112 cases who diagnosed as AMI without PCI were divided randomly into observation group(58 cases using sequential atorvastatin)and control group(54 cases using Atorvastatin,20 mg,daily),the major adverse cardiovascular events(MACE) of all patients in six months after AMI were analyzed,and measured the serum levels of high sensitivity C-reaction protein(hsCRP) within 24 hours before therapy,six months after therapy respectively,and observed the drug-side effects.Results Compared to the control group,the MACE in observation group decreased with statistical significance(P < 0.05).Compared to the control group,the serum levels of hsCRP in observation group decreased with statistical significance(P < 0.05).There was no significant difference between the observation and the control group in the muscle toxicity and hepatotoxicity.Conclusion Stains sequential therapy can significantly reduce the MACE in patients without PCI six months after AMI.